Welcome to our dedicated page for Cardinal Health news (Ticker: CAH), a resource for investors and traders seeking the latest updates and insights on Cardinal Health stock.
Cardinal Health, Inc. distributes pharmaceuticals and specialty products and manufactures and distributes medical, laboratory, home-health and direct-to-patient products and services. The company also operates nuclear pharmacies and manufacturing facilities and provides performance and data solutions for healthcare customers.
Recurring company updates cover financial results and fiscal outlooks, dividend actions, share repurchases, debt activity, segment performance in Global Medical Products and Distribution, at-Home Solutions, Nuclear and Precision Health Solutions and OptiFreight Logistics. Other developments include biosimilars and advanced-therapy research reports, Actinium-225 production capacity for radiopharmaceutical applications, and board governance changes.
Cardinal Health (NYSE: CAH) said its Board approved a quarterly dividend increase to $0.5158 per share, to be paid from the company’s capital surplus. The dividend is payable on July 15, 2026 to shareholders of record at the close of business on July 1, 2026.
Cardinal Health (NYSE: CAH) reported Q3 FY26 revenue of $60.9 billion, up 11% year-over-year. GAAP operating earnings fell to $509 million (–30%) and GAAP diluted EPS to $1.69 (–20%) after a $184 million goodwill impairment. Non-GAAP operating earnings rose to $956 million and non-GAAP diluted EPS to $3.17. The company raised FY26 non-GAAP EPS guidance to $10.70–$10.80, narrowed adjusted free cash flow to $3.3–$3.7 billion, reduced debt, and completed year-to-date buybacks of $1.0 billion.
Cardinal Health (NYSE: CAH) released its 2026 Advanced Therapies Report: Perspectives on Community Expansion, reporting provider momentum to move gene-, cell- and tissue-based treatments into outpatient and community settings to improve access and patient experience.
The report surveyed >160 clinicians and administrators, notes 61 approved advanced therapies in the U.S. today and projects that total will nearly triple by 2030, while highlighting infrastructure, staffing and partnership needs for safe community delivery.
Cardinal Health (NYSE:CAH) announced on April 1, 2026 an expansion of Actinium-225 (Ac-225) production at its Center for Theranostics Advancement in Indianapolis. The company added a high-capacity production line to its DMF, quadrupled weekly output since late 2024, and plans further capacity increases in 2026 to support clinical and future commercial targeted alpha therapies.
The expanded supply has supported more than 15 clinical trials and aims to improve access for developers of therapies for prostate, neuroendocrine, breast, colon, melanoma, and lymphoma.
Cardinal Health (NYSE: CAH) will release third-quarter fiscal 2026 results on April 30, 2026 before the New York Stock Exchange opens. A webcast discussion begins at 8:30 a.m. Eastern. Slides and a replay will be available on the company Investor Relations page for 12 months; no access code is required.
Cardinal Health (NYSE: CAH) appointed Patricia A. Hemingway Hall as Chair of the Board, effective March 23, 2026, succeeding Gregory B. Kenny upon his retirement. Ms. Hemingway Hall has served on the board since 2013 and chaired the Governance and Sustainability Committee for nearly seven years.
The company said Ms. Hemingway Hall brings deep healthcare leadership as former CEO of Health Care Service Corporation. Cardinal Health reiterated confidence in its fiscal 2026 outlook and will release third quarter fiscal 2026 earnings on April 30.
Cardinal Health (NYSE: CAH) released its 2026 Biosimilars Report highlighting measured cost savings and high provider confidence in biosimilars across physician practices. The report cites $56 billion in U.S. savings since 2015 and projects up to $181 billion in future savings if market and policy conditions align.
Key metrics: 99% of surveyed providers feel comfortable explaining biosimilars, oncology biosimilars reach an average 81% market share within five years, and nearly 25 biosimilars are expected to receive FDA approval over the next two years.
Cardinal Health (NYSE: CAH) said its Board approved a quarterly dividend of $0.5107 per share, payable April 15, 2026 to shareholders of record at the close of business April 1, 2026. The dividend will be paid out of the company's capital surplus.
Cardinal Health (NYSE: CAH) reported Q2 FY2026 revenue of $65.6 billion (+19% Y/Y), GAAP operating earnings of $707 million (+29%) and GAAP diluted EPS of $1.97 (+19%). Non-GAAP operating earnings were $877 million (+38%) and non-GAAP EPS was $2.63 (+36%).
The company raised FY2026 non-GAAP EPS guidance to $10.15–$10.35, completed $750 million of share repurchases year-to-date, and reached its targeted leverage range.
Cardinal Health (NYSE:CAH) raised its fiscal 2026 non‑GAAP diluted EPS outlook to at least $10.00 (from $9.65–$9.85) and expects Specialty revenues >$50 billion in fiscal 2026, a 16% three‑year CAGR. Management cited strong execution across five segments and will provide more detail on the Feb 5, 2026 earnings call.
The company highlighted BioPharma Solutions' expected >30% revenue growth in fiscal 2026, Sonexus™ serving >1 million patients, successful contract transitions ahead of the Jan 1, 2026 Medicare Drug Price Negotiation changes, and the new ContinuCare™ Pathway program (Publix enrolled ~1,400 pharmacies; program covers >11,000 pharmacies).